 |
|
|
|
 |
A Phase I Study of Induction Therapy with Cytarabine, High-Dose Mitoxantrone, and Dasatinib for Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
[Protocol 09-046]
- Full Title :
- PHASE I STUDY OF INDUCTION THERAPY WITH CYTARABINE, HIGH-DOSE MITOXANTRONE AND DASATINIB FOR PATIENTS WITH PHILADELPHIA-CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): ALL-6 PROTOCOL
- Purpose :
The combination of cytarabine and mitoxantrone is a standard chemotherapy for acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome. Adding the drug dasatinib, which has been shown to be effective against ALL when used alone, to induction therapy with cytarabine and mitoxantrone may be useful for killing even more ALL cells than either treatment alone.
In this study, researchers are seeking to find the most effective safe dose of dasatinib that can be given with cytarabine and mitoxantrone in patients with Philadelphia chromosome-positive leukemia.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of previously untreated Philadelphia chromosome-positive ALL or CML in lymphoid blast crisis.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Mark Weiss at 212-639-5827.
|
|
|
|
|
